$50,000 of HUMACYTE lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to Medicare reimbursement for biological products. Issues related to Medicare reimbursement for biological products. Issues related to supporting access to biologic products to treat warfighters. Supporting funding for procurement of biologic products to treat post-combat trauma. Issues related to supporting access to biologic products to treat warfighters."
You can find more data on corporate lobbying on Quiver Quantitative.
HUMA Hedge Fund Activity
We have seen 78 institutional investors add shares of HUMA stock to their portfolio, and 54 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 1,485,152 shares (+129.5%) to their portfolio in Q4 2025, for an estimated $1,426,488
- BLACKROCK, INC. added 1,443,324 shares (+14.6%) to their portfolio in Q4 2025, for an estimated $1,386,312
- BNP PARIBAS FINANCIAL MARKETS added 1,009,097 shares (+1100.0%) to their portfolio in Q4 2025, for an estimated $969,237
- UBS GROUP AG added 976,275 shares (+48.8%) to their portfolio in Q4 2025, for an estimated $937,712
- VANGUARD GROUP INC added 896,916 shares (+11.9%) to their portfolio in Q4 2025, for an estimated $861,487
- CITADEL ADVISORS LLC added 673,479 shares (+75.4%) to their portfolio in Q4 2025, for an estimated $646,876
- GEODE CAPITAL MANAGEMENT, LLC added 624,220 shares (+20.2%) to their portfolio in Q4 2025, for an estimated $599,563
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HUMA Analyst Ratings
Wall Street analysts have issued reports on $HUMA in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/09/2026
- D. Boral Capital issued a "Buy" rating on 11/20/2025
- Benchmark issued a "Buy" rating on 11/13/2025
To track analyst ratings and price targets for HUMA, check out Quiver Quantitative's $HUMA forecast page.
HUMA Price Targets
Multiple analysts have issued price targets for $HUMA recently. We have seen 6 analysts offer price targets for $HUMA in the last 6 months, with a median target of $1.25.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $25.0 on 04/21/2026
- Matt Miksic from Barclays set a target price of $1.5 on 04/08/2026
- Bruce D. Jackson from Benchmark set a target price of $1.0 on 03/31/2026
- Joshua Jennings from TD Cowen set a target price of $1.0 on 03/30/2026
- Allison Bratzel from Piper Sandler set a target price of $1.0 on 03/30/2026
- Ryan Zimmerman from BTIG set a target price of $3.0 on 03/27/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
